After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks. Approximately 44 million COPD cases were recorded in 2023 in the 7MM ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...
GlobalData on MSN2d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticariaThe FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback